Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 1917-1923

  Wongwiwatthananukit, Supakit ^a   Sansanayudh, Nakarin ^b   Dhummauppakorn, Rawadee ^a   Kitiyadisai, Chutiporn ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c Prapinklao Hospital   (Thailand)

Author keywords

Dosing; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; CORTICOSTEROID; CREATINE KINASE; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; OPEN STUDY; OUTPATIENT CARE; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33751001363     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H124     Document Type: Article

References (26)

1. Epidemiology and burden of disease. World Health Organization, Geneva 2003. Causes of death. Global, regional and country-specific estimates of deaths by cause, age and sex. www.who.int/mip/2003/other_ documents/en/causesofdeath. pdf (accessed 2004 Sept 9).
2. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
4. Talbert RL. Hyperlipidemia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. Stamford, CT: Appleton & Lange, 2002:395-417.
5. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2003;361:7-22.
6. Brewer HB. NCEP and next steps: rosuvastatin and the therapeutic index, Medscape Cardiology 2004;8:1-10. www.medscape.com/viewarticle/466100 (accessed 2004 Apr 12).
7. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
8. Quirk J, Thornton M, Kirkpatrik P. Fresh from the pipeline: rosuvastatin calcium. Nature Rev Drug Discov 2003;2:769-70.
9. Copher HR, Stewart RD. Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia. Pharmacotherapy 2002;22:1110-6.
10. Dennis VC, Britton ML, Sirmans SM, Letassy NA, Freeman DA. The use of alternate-day lovastatin in hypercholesterolemic men. Ann Pharmacother 1997;31:708-12.
11. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999;83:1135-7.
12. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dosing of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS). Am Heart J 2002;144:674-7.
13. Metz CA, Lucas KH. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction. Ann Pharmacother 2001;35:496-500. DOI 10.1345/aph.10164
14. Phruttisunakon S, Piamsomboon C, Utiswannakul A. A comparison of efficacy and tolerability of lipid lowering between atorvastatin 10 mg daily and 10 mg every other day in patients with hypercholesterolaemia. ASEAN Heart J 2003;10:1-7.
15. Rindone JP, Achacoso R, Bledsoe R. Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol >160 mg/dL. Am J Cardiol 1995;76:312-3.
16. Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998;18:836-9.
17. Van L. Every other day statin therapy. Pharmacist's letter/Prescriber's letter 2002;18:detail document number 181102. (accessed 2004 Apr 12).
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
19. FDA Advisory Committee. Crestor (ZD4522, rosuvastatin calcium) tablets. FDA Advisory Committee Meeting Briefing Document NDA 21-366 for the use of Crestor. Rockville, MD: Food and Drug Administration, 2003:1-40.
20. Jones PH. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;93:152-60.
21. US Food and Drug Administration. FDA Drug Approvals List. www.fda. gov/cder/drug/advisory/crestor_3_2005.htm (accessed 2005 Apr 12).
22. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiol Drug Rev 2002;20:303-28.
23. Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92(suppl):23K-9K.
24. Olsson AG, Pears J, McKellar J, Mizan J, Riza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-8.
25. Blasetto JW, Stein EA, Brown WV, Chitra R, Riza A. Efficacy of rosuvastatin compared with other statins at selecting starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91(suppl):3C-10C.
26. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchison HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91(suppl):11C-9C.